The estimated Net Worth of Michael T. Constantino is at least $4.24 Thousand dollars as of 23 May 2022. Michael Constantino owns over 16,000 units of 9 Meters Biopharma stock worth over $4,236 and over the last 4 years Michael sold NMTR stock worth over $0.
Michael has made over 3 trades of the 9 Meters Biopharma stock since 2020, according to the Form 4 filled with the SEC. Most recently Michael bought 16,000 units of NMTR stock worth $7,680 on 23 May 2022.
The largest trade Michael's ever made was buying 34,108 units of 9 Meters Biopharma stock on 20 August 2020 worth over $25,581. On average, Michael trades about 9,730 units every 92 days since 2020. As of 23 May 2022 Michael still owns at least 60,508 units of 9 Meters Biopharma stock.
You can see the complete history of Michael Constantino stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is C/O 9 METERS BIOPHARMA, INC., 4509 CREEDMOOR ROAD, SUITE 201, RALEIGH, NC, 27612.
Over the last 5 years, insiders at 9 Meters Biopharma have traded over $20,934,964 worth of 9 Meters Biopharma stock and bought 2,247,050 units worth $1,572,701 . The most active insiders traders include Israel Gp Ltd.Orbi Med Isra..., Mark A Sirgo, and John Temperato. On average, 9 Meters Biopharma executives and independent directors trade stock every 35 days with the average trade being worth of $45,283. The most recent stock trade was executed by Bethany Sensenig on 21 April 2023, trading 9,100 units of NMTR stock currently worth $11,011.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
9 Meters Biopharma executives and other stock owners filed with the SEC include: